Prediction of response to interferon therapy in multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Prediction of response to interferon therapy in multiple sclerosis. / Sellebjerg, F; Søndergaard, Helle Bach; Koch-Henriksen, N; Sørensen, P S; Oturai, A B.

I: Acta Neurologica Scandinavica, Bind 130, Nr. 4, 2014, s. 268-275.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sellebjerg, F, Søndergaard, HB, Koch-Henriksen, N, Sørensen, PS & Oturai, AB 2014, 'Prediction of response to interferon therapy in multiple sclerosis', Acta Neurologica Scandinavica, bind 130, nr. 4, s. 268-275. https://doi.org/10.1111/ane.12269

APA

Sellebjerg, F., Søndergaard, H. B., Koch-Henriksen, N., Sørensen, P. S., & Oturai, A. B. (2014). Prediction of response to interferon therapy in multiple sclerosis. Acta Neurologica Scandinavica, 130(4), 268-275. https://doi.org/10.1111/ane.12269

Vancouver

Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB. Prediction of response to interferon therapy in multiple sclerosis. Acta Neurologica Scandinavica. 2014;130(4):268-275. https://doi.org/10.1111/ane.12269

Author

Sellebjerg, F ; Søndergaard, Helle Bach ; Koch-Henriksen, N ; Sørensen, P S ; Oturai, A B. / Prediction of response to interferon therapy in multiple sclerosis. I: Acta Neurologica Scandinavica. 2014 ; Bind 130, Nr. 4. s. 268-275.

Bibtex

@article{ca9a9c45dfda4c91903216e26c871692,
title = "Prediction of response to interferon therapy in multiple sclerosis",
abstract = "OBJECTIVE: Single nucleotide polymorphisms (SNPs) in the genes encoding interferon response factor (IRF)-5, IRF-8 and glypican-5 (GPC5) have been associated with disease activity in multiple sclerosis (MS) patients treated with interferon (IFN)-β. We analysed whether SNPs in the IRF5, IRF8 and GPC5 genes are associated with clinical disease activity in MS patients beginning de novo treatment with IFN-β.METHODS: The SNPs rs2004640, rs3807306 and rs4728142 in IRF5, rs13333054 and rs17445836 in IRF8 and rs10492503 in GPC5 were genotyped in 575 patients with relapsing-remitting MS followed prospectively after the initiation of their first treatment with IFN-β.RESULTS: 62% of patients experienced relapses during the first 2 years of treatment, and 32% had disability progression during the first 5 years of treatment. Patients with a pretreatment annualized relapse rate >1 had an increased risk of relapse (hazard ratio 1.53, 95% confidence interval 1.24-1.90) and progression (hazard ratio 1.48, 95% confidence interval 1.10-1.99) on treatment and patients with breakthrough relapses in the form of relapses during the first 2 years of treatment had an increased risk of progression during the first 5 years of treatment (hazard ratio 2.04, 95% confidence interval 1.47-2.85).The gene variants in IRF5, IRF8 and GPC5 were not associated with risk of relapse or disease progression.CONCLUSIONS: Pretreatment relapse rate and clinical disease activity during the first 2 years of treatment may be associated with disease progression in MS patients treated with IFN-β. Genetic analysis of the studied gene variants do not provide additional information.",
keywords = "Adult, Disease Progression, Female, Genetic Predisposition to Disease, Glypicans, Humans, Interferon Regulatory Factors, Interferon-beta, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Polymorphism, Single Nucleotide, Recurrence",
author = "F Sellebjerg and S{\o}ndergaard, {Helle Bach} and N Koch-Henriksen and S{\o}rensen, {P S} and Oturai, {A B}",
note = "{\textcopyright} 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2014",
doi = "10.1111/ane.12269",
language = "English",
volume = "130",
pages = "268--275",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Prediction of response to interferon therapy in multiple sclerosis

AU - Sellebjerg, F

AU - Søndergaard, Helle Bach

AU - Koch-Henriksen, N

AU - Sørensen, P S

AU - Oturai, A B

N1 - © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2014

Y1 - 2014

N2 - OBJECTIVE: Single nucleotide polymorphisms (SNPs) in the genes encoding interferon response factor (IRF)-5, IRF-8 and glypican-5 (GPC5) have been associated with disease activity in multiple sclerosis (MS) patients treated with interferon (IFN)-β. We analysed whether SNPs in the IRF5, IRF8 and GPC5 genes are associated with clinical disease activity in MS patients beginning de novo treatment with IFN-β.METHODS: The SNPs rs2004640, rs3807306 and rs4728142 in IRF5, rs13333054 and rs17445836 in IRF8 and rs10492503 in GPC5 were genotyped in 575 patients with relapsing-remitting MS followed prospectively after the initiation of their first treatment with IFN-β.RESULTS: 62% of patients experienced relapses during the first 2 years of treatment, and 32% had disability progression during the first 5 years of treatment. Patients with a pretreatment annualized relapse rate >1 had an increased risk of relapse (hazard ratio 1.53, 95% confidence interval 1.24-1.90) and progression (hazard ratio 1.48, 95% confidence interval 1.10-1.99) on treatment and patients with breakthrough relapses in the form of relapses during the first 2 years of treatment had an increased risk of progression during the first 5 years of treatment (hazard ratio 2.04, 95% confidence interval 1.47-2.85).The gene variants in IRF5, IRF8 and GPC5 were not associated with risk of relapse or disease progression.CONCLUSIONS: Pretreatment relapse rate and clinical disease activity during the first 2 years of treatment may be associated with disease progression in MS patients treated with IFN-β. Genetic analysis of the studied gene variants do not provide additional information.

AB - OBJECTIVE: Single nucleotide polymorphisms (SNPs) in the genes encoding interferon response factor (IRF)-5, IRF-8 and glypican-5 (GPC5) have been associated with disease activity in multiple sclerosis (MS) patients treated with interferon (IFN)-β. We analysed whether SNPs in the IRF5, IRF8 and GPC5 genes are associated with clinical disease activity in MS patients beginning de novo treatment with IFN-β.METHODS: The SNPs rs2004640, rs3807306 and rs4728142 in IRF5, rs13333054 and rs17445836 in IRF8 and rs10492503 in GPC5 were genotyped in 575 patients with relapsing-remitting MS followed prospectively after the initiation of their first treatment with IFN-β.RESULTS: 62% of patients experienced relapses during the first 2 years of treatment, and 32% had disability progression during the first 5 years of treatment. Patients with a pretreatment annualized relapse rate >1 had an increased risk of relapse (hazard ratio 1.53, 95% confidence interval 1.24-1.90) and progression (hazard ratio 1.48, 95% confidence interval 1.10-1.99) on treatment and patients with breakthrough relapses in the form of relapses during the first 2 years of treatment had an increased risk of progression during the first 5 years of treatment (hazard ratio 2.04, 95% confidence interval 1.47-2.85).The gene variants in IRF5, IRF8 and GPC5 were not associated with risk of relapse or disease progression.CONCLUSIONS: Pretreatment relapse rate and clinical disease activity during the first 2 years of treatment may be associated with disease progression in MS patients treated with IFN-β. Genetic analysis of the studied gene variants do not provide additional information.

KW - Adult

KW - Disease Progression

KW - Female

KW - Genetic Predisposition to Disease

KW - Glypicans

KW - Humans

KW - Interferon Regulatory Factors

KW - Interferon-beta

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Polymorphism, Single Nucleotide

KW - Recurrence

U2 - 10.1111/ane.12269

DO - 10.1111/ane.12269

M3 - Journal article

C2 - 24943672

VL - 130

SP - 268

EP - 275

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 4

ER -

ID: 138180008